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Introduction: Interleukin-6 (IL-6) can activate downstream signal-
ing pathways in lung cancer cells, such as the STAT3 pathway, and is 
reported to be produced by tumor cells with activating EGFR muta-
tions. We examined IL-6/STAT3 in lung cancer tumor tissues and 
the effects of siltuximab, a neutralizing antibody to human IL-6, in 
mouse models of lung cancer.
Methods: IL-6 and STAT3 activation levels were compared with 
tumor histology and presence of KRAS mutations in snap-frozen, 
non–small-cell lung cancer tumors. The effects of siltuximab alone 
or in combination with erlotinib were examined in mouse xenograft 
models constructed using three cell line xenograft models and one 
primary explant mouse model. We examined the influence of cancer-
associated fibroblasts (CAFs) on tumor growth and siltuximab effects.
Results: IL-6 levels were higher in tumors of squamous cell versus 
adenocarcinoma histology and were not associated with presence of 
KRAS mutations. Tyrosine phosphorylation status of STAT3 did not 
correlate with tumor IL-6 levels. Serine phosphorylation of STAT3 
was correlated with KRAS mutation status. Both tumor and stromal 
cells contributed to total IL-6 within tumors. Siltuximab had minimal 
effect as a single agent in xenografts with tumor cells alone; however, 
in models coadministered with CAFs, siltuximab had more potent 
effects on tumor inhibition. We observed no effects of combined 
erlotinib and siltuximab.
Conclusions: IL-6 is elevated in subsets of human NSCLCs, espe-
cially with squamous cell histology. Tumors supported by stromal 
production of IL-6 seem to be the most vulnerable to tumor growth 
inhibition by siltuximab.
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Lung cancer continues to be the leading form of cancer death in both men and women in the United States. Given 
the inherent insensitivity of tumor cells to cytotoxic agents, 
identifying the drivers of lung cancer growth, survival, and 
metastasis is critical, as is the development of novel therapeu-
tics. Members of the signal transducer and activator of tran-
scription (STAT) family of transcription factors are potential 
targets in lung cancer and other cancers.1–3 STAT proteins are 
activated by upstream cytokines and tyrosine kinase signaling 
and control genes that regulate cancer hallmarks.4 Constitutive 
STAT3 activation is associated with cancers with poor prog-
nosis through its antiapoptotic and proliferative effects, and 
effects on immune evasion and tumor angiogenesis.5 STAT3 
can become constitutively active in cancer cells through vari-
ous cellular pathways, including upregulation of cytokines 
such as interleukin-6 (IL-6). In addition to cytokines, tyrosine 
kinases, such as receptor tyrosine kinases (epidermal growth 
factor receptor (EGFR), for example) and non-receptor tyro-
sine kinases (SRC family kinases), can also drive STAT3 sig-
naling.6 Indirect or direct inhibition of STAT3 has been shown 
to affect tumor formation through inhibition of cell growth, 
induction of apoptosis, and/or inhibition of tumor angiogen-
esis. A number of recent studies have found activated STAT3 
in lung cancer cell lines and tissues, thus suggesting a func-
tional role for this target in subsets of lung cancer.7–11 Lung 
cancers with EGFR mutation have been reported to have more 
abundant IL-6 production, which drives STAT3 signaling and 
in some cases may drive resistance to EGFR tyrosine kinase 
inhibitors (TKIs).12,13
Our previous studies examined STAT protein activation 
in lung cancer cell lines, including those with activating muta-
tions in EGFR, and examined upstream kinases responsible 
for STAT3 phosphorylation and activation using small mol-
ecules, antibodies, and RNA interference. In these studies, we 
found more pronounced STAT3 activation in cells with acti-
vating EGFR mutations, yet inhibition of EGFR activity had 
no effect on STAT3 activation.9 Inhibition of JAK1 with small 
molecules or RNA interference resulted in loss of STAT3 
tyrosine phosphorylation and inhibition of cell growth.10 
Siltuximab (CNTO 328), an IL-6 neutralizing antibody, could 
inhibit STAT3 tyrosine phosphorylation in a cell-dependent 
manner. In H1650 cells harboring an activating EGFR muta-
tion, siltuximab inhibited STAT3 tyrosine phosphorylation, 
resulting in inhibition of lung cancer cell growth in vivo. 
In addition, when siltuximab was combined with the EGFR 
inhibitor erlotinib, there was a more pronounced inhibition of 
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STAT3 transcriptional activity. Our results suggest that indi-
rect attacks on JAK1-STAT3 using an IL-6 neutralizing anti-
body with or without EGFR inhibition can inhibit lung cancer 
growth in lung cancer subsets.
Additional questions remain to be answered to fully real-
ize the potential to translate these findings into early-phase clin-
ical trials and to explore the utility of siltuximab in advanced 
lung cancer. In this study, we sought answers to the following 
questions. First, what is the incidence of tumors demonstrating 
constitutive IL-6 signaling, as this could represent an enriched 
group for future clinical trials. Second, how should siltuximab 
be combined with other molecular agents and in which tumor 
subtype? To explore these questions, we examined IL-6 and 
STAT3 signaling in 100 snap-frozen human non–small-cell 
lung cancer (NSCLC) tumor tissues and examined their histol-
ogy and oncogene mutation status. We then explored efficacy 
of siltuximab with the EGFR-TKI erlotinib in three lung can-
cer cell line xenograft models. As part of these studies, we also 
studied the impact of cancer-associated fibroblasts (CAF) on 
tumor growth and sensitivity to siltuximab and erlotinib. CAF 
cells are known to be large producers of IL-6 in the cancer 
microenvironment, and we hypothesized that these heterotypic 
models may better recapitulate human lung cancers. Finally, 
we examined siltuximab in a primary explant mouse model of 
lung cancer. Our ultimate goal was to reveal the pattern of IL-6 
to downstream STAT3 activation in NSCLC and to provide fur-
ther evidence to guide future clinical cancer therapies.
MATERIALS AND METHODS
Materials
H1650 cells were obtained from ATCC (Manassas, VA), 
H157 cells were obtained from Dr. John Minna (University 
of Texas Southwestern University, Dallas, TX), and H322 
cells were obtained from Dr. Paul Bunn (University of 
Colorado, Denver, CO). Cancer-associated fibroblasts (cata-
log #PC60199A1-CAF-P0) were obtained from Asterand 
(Detroit, MI) and were p0 fibroblasts isolated from tumor 
region of lung from a 77-year-old Caucasian female with 
Stage I Squamous cell carcinoma of the lung. All cell lines 
have been maintained in a central repository at Moffitt since 
2008. All cell lines had been authenticated by STR analysis 
(ACTG Inc., Wheeling, IL) as of September 2010, and all cells 
had been routinely tested and were negative for mycoplasma 
(PlasmoTest, InvivoGen, San Diego, CA). Erlotinib was pur-
chased from ChemieTek (Indianapolis, IN). Siltuximab and 
murine anti-IL-6 antibody was supplied by Janssen R&D. 
Cells (5000) were grown in RPMI medium with 10% fetal 
bovine serum and seeded in 96-well plates for cell viability 
assays, as previously described.10 We used the CellTiter-Glo 
Luminescent Cell Viability Assay kit (Promega, Madison, WI) 
for cell viability assays, following the manufacturer’s instruc-
tions. For Western blot analyses, cells were lysed in RIPA 
buffer with protease inhibitor cocktail tablets (Roche), as pre-
viously described.10 Total STAT3 antibodies were purchased 
from Santa Cruz Biotechnology, and tyrosine phosphory-
lated STAT3 (PY-STAT3; Tyr705) antibodies were from Cell 
Signaling Technologies (Cambridge, MA). Mouse rIL-6 was 
from R&D Systems (St Paul, MN).
Luminex Bio-Plex Assay and DNA 
Mutation Sequencing for Tumor Tissue
Frozen NSCLC specimens from 100 patients were 
obtained from the Moffitt Tissue Core repository. Collected 
samples were from patients who had provided written informed 
consent to participate in the Institutional Review Board-
approved Moffitt Total Cancer Care protocol. We used the 
Multiplex Luminex assay to evaluate STAT3 activities and IL-6 
expression levels using protein lysates from the frozen tissue. 
The Multiplex Luminex assay measured levels of PY-STAT3 
(Tyr705), serine phosphorylated STAT3 (PS-STAT3; Ser727), 
and IL-6, with experiments run in triplicate as previously 
described.10 A standardized curve was used to calculate the IL-6 
concentration using recombinant human IL-6 (BD Pharmagen) 
along a range from 0 to 10,000 pg (Supplementary Figure 1, 
SDC 1, http://links.lww.com/JTO/A591). Genomic DNA was 
examined for EGFR mutations on exons 18, 19, 20, and 21 and 
for KRAS mutations on exons 1 and 2. The sequencing results 
were analyzed using Lasergene (DNASTAR, Madison, WI), 
which measured the correlation between STAT3 activation and 
IL-6 expression in NSCLC cells.
Immunohistochemistry
Staining was performed on a Ventana Discovery XT 
automated system (Ventana Medical Systems, Tucson, AZ) as 
per manufacturer’s protocol with proprietary reagents. Slides 
were deparaffinized with EZ Prep solution (Ventana) using 
an automated system. Ribo CC buffer (#760-107, Ventana) 
was used for heat-induced epitope retrieval. Murine mono-
clonal antibody to IL-6 (#ab9324, Abcam, Cambridge, MA) 
was used at a 1:100 concentration in Dako antibody diluent 
(Carpenteria, CA) for 32 minutes and detected with Ventana 
OmniMap antimouse secondary antibody for 16 minutes. 
Rabbit monoclonal antibody to PY-STAT3(Y705; #9145, 
Cell Signaling Technologies, Danvers, MA) was used at a 
1:100 concentration in PSS diluent (Carpenteria, CA) for 
60 minutes and detected with Ventana UltraMap anti-rabbit 
secondary antibody for 20 minutes. Signal was detected with 
Ventana ChromoMap kit and slides were counterstained with 
hematoxylin. Slides were then dehydrated, coverslipped, and 
imaged on an Aperio SlideScannerXT (Carlsbad, CA). For 
PY-STAT3(Y705), the Aperio Spectrum nuclear algorithm 
was used to quantify nuclear staining.
Xenograft Mouse Model
All animal protocols were approved by our Institutional 
Animal Care and Use Committee. Female CD-1 nu/nu mice 
were obtained from Charles River Laboratories (Wilmington, 
MA). The mice were injected with H1650 (adenocarcinoma), 
H322 (adenocarcinoma), or H157 (squamous) cell lines 
either alone or combined with CAFs in a 1:1 ratio. Cells were 
injected at a single subcutaneous site on the mouse flank 
(5 million cells per site mixed with 0.1 ml of Matrigel; BD 
Pharmingen, Franklin Lakes, NJ). After 10–14 days of tumor 
growth, mice were randomly divided into four groups with 
15 mice in each treatment group: control, erlotinib only, anti-
IL-6 antibodies only, and combination (erlotinib plus anti-
IL-6 antibodies). Treatment was initiated when tumor size 
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reached a volume of approximately 50–200 mm3. Siltuximab 
(10 mg/kg) was combined with anti-murine IL-6 monoclonal 
antibody (10 mg/kg) and administered three times per week 
intraperitoneally in phosphate-buffered saline (PBS) dilution. 
Erlotinib (50 mg/kg) was given daily by oral gavage in dilution 
of 0.5% of hydroxypropyl methylcellulose (Sigma, St. Louis, 
MO). Control animals received intraperitoneal injections of 
100 μl PBS and 0.5% (w/v) hydroxypropyl methylcellulose by 
mouth, both as placebo. Tumor volume (in mm3), calculated 
as tumor length times width times width divided by two, and 
body weight were measured two or three times per week.
Fresh lung adenocarcinoma tissue (EGFR wild-type, 
KRAS wild-type) was obtained from surgical specimens of 
patients undergoing tumor resection at the Moffitt Cancer 
Center and established as subcutaneous xenografts initially 
in nu/nu mice (F1 generation). In brief, primary tumor speci-
mens were acquired at initial surgery from early-stage non–
small-cell lung cancer (NSCLC) patients, cut into small 
pieces and immediately subcutaneously transplanted in immu-
nodeficient nu/nu mice. Consent for use of human tumor tis-
sue was obtained from patients and the study was approved by 
the University of South Florida Institutional Review Board. 
The explanted tumor tissues from early tumor passages were 
maintained with approximately two or three passages. Frozen 
tumor xenografts from this initial passage (F3) were reim-
planted subcutaneously in groups of five NOD/SCID mice 
(Taconic, Hudson, NY) mice for each tumor sample, with two 
small pieces reimplanted per mouse (F4 generation). NOD/
SCID mice were selected as tumors had better growth charac-
teristics in our experience. When tumor size reached 1.5 cm, 
tumors were harvested, divided into small 3 × 3 × 3 mm pieces, 
and transplanted into another 18–22 mice, with one tumor per 
mouse (F5 generation). Thirty mice received subcutaneous 
implants of F5 tumor tissue and were observed for approxi-
mately 4–5 weeks for tumor volume growth. Treatment 
was started when tumor volume reached approximately 
10–20 mm3. Siltuximab (10 mg/kg) was given twice per week 
intraperitoneally in PBS dilution, whereas control animals 
received intraperitoneal injections of 100 μl PBS.
Statistical Methods
For tumor tissue experiments, statistical assays were 
designed to identify any significant relationships between 
profiles and relevant patient characteristics. Three continuous 
measures of IL-6, PY-STAT3, and PS-STAT3 were collected 
and then averaged. Correlations between two group variables 
were examined by Spearman nonparametric correlation with 
correlation coefficient (r). The unpaired t test with Welch’s cor-
rection was used to examine significant differences between 
two study groups. Because of small, unequal, nonparametric 
sets with different variances and numbers, the Kruskal-Wallis 
one-way analysis of the variance, a nonparametric test, was 
used to compare three or more unpaired groups. Anderson-
Darling statistics were used to examine whether log-trans-
formed results were close to normal distribution. We used log
2
 
transformation for tumor volume to allow volume measure-
ments to approximate to normal distribution, because data 
were not normally distributed. Descriptive statistics indicated 
the mean, median, standard deviation, minimum, and maxi-
mum. Tukey’s multiple comparisons (compare all pairs of 
drug treatment group) were used to examine the one-way 
analysis of the variance for treatment groups. Significant dif-
ferences are indicated with p values. For all statistical analyses 
and graphs, we used GraphPad version 5.0.
RESULTS
Patterns of IL-6 and STAT3 Activation in NSCLC
We studied 100 NSCLC human specimens for IL-6 and 
downstream STAT3 activation and correlated these results 
with tumor histology and presence of KRAS mutations. We 
also examined whether IL-6 levels were associated with pat-
terns of STAT3 activation. Tumor tissue characteristics are 
shown in Table 1. All stages of disease were represented, 
although most were from earlier stages amenable to surgical 
resection. Overall, nearly 50% were characterized as adeno-
carcinoma, 25% were characterized as squamous cell carci-
noma, with the remaining tissues characterized as NSCLC, 
not otherwise specified (NOS). Our sequencing analyses indi-
cated that 5% of our tissues were EGFR mutant and 25% were 
KRAS mutant. Because of the low number of EGFR mutants, 
we were only able to compare IL-6 and STAT3 signaling 
between the KRAS-mutant and wild-type tumors.
As shown in Figure 1A, overall, over 70% of the tumors 
demonstrated a higher level of PY-STAT3 (Tyr705) and IL-6 
than a prototypical NSCLC cell line, such as A549, which 
has more modest expression of IL-6 and PY-STAT3 (Tyr705; 
data not shown). When we measured the correlation between 
IL-6 and PY-STAT3 and IL-6 and PS-STAT3, we did not find a 
strong correlation between PY-STAT3 and IL-6 (r = −0.1365, 
p > 0.05) and PS-STAT3 and IL-6 (r = 0.219, p > 0.05). Similar 
analyses within adenocarcinoma, squamous cell lung cancer 
and NSCLC NOS also failed to demonstrate any significant 
TABLE 1.  Characterization of the Tumor Tissues
Total Samples (N = 100)
Tumor, Node, Metastasis Path Stage Group, n
  I 33
  II 22
  III 16
  IV 6
  Uncharacterized 23
Histology, n
  Adenocarcinoma 50
  Squamous cell carcinoma 25
  NSCLC (uncharacterized) 25
Mutations in EGFR and KRAS, n
  KRAS 25
  EGFR 5
  Neither 70
One-hundred frozen non–small-cell lung carcinoma (NSCLC) specimens were 
obtained from our Institution’s Tissue Core Facility and evaluated for the tumor type 
and disease stage. The mutations of EGFR and KRAS were identified by genomic 
polymerase chain reaction.
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correlations (data not shown). These data suggest that STAT3 
phosphorylation is not a good surrogate marker of total tumor 
IL-6 levels. As shown in Figure 1B, IL-6 levels in the squa-
mous cell carcinoma group were nearly twofold higher than 
in the adenocarcinoma group. No significant differences of 
PY-STAT3 and PS-STAT3 were found between these his-
tological groups. However, as shown in Figure 1C, we did 
find that PS-STAT3 levels in the KRAS mutation group were 
higher than those in wild-type tumors, suggesting that high 
PS-STAT3 levels may contribute to tumorigenesis in KRAS 
mutation setting (p < 0.05).
We used IL-6 immunohistochemistry to examine the 
cell source of the IL-6 found in our tumors and performed 
a focused analysis on 10 cases that had high levels of IL-6 
detected in tumor lysates. Interestingly, we identified two gen-
eralized patterns. First, within the tumor, we observed tumor 
cells that expressed little IL-6 and stromal cells that produced 
abundant levels of IL-6 (Fig. 1D, top panel). Second, within 
FIGURE 1.  Interleukin-6 (IL-6) and 
STAT3 activation patterns in non–small-
cell lung cancer (NSCLC) specimens. 
A, histogram indicating distribution 
of IL-6, PY-STAT3, and PS-STAT3 levels 
in frozen NSCLC specimens from 100 
patients by Luminex multiplex assay. 
(B) Bar graph indicating differences 
in IL-6 levels in adenocarcinoma and 
squamous cell carcinoma tissue based 
on tumor histology. IL-6 levels (pg/
mg) were calculated by standardized 
regression linear curve and normal-
ized with the protein extracts from 
tissue (mg). p values indicate com-
parisons versus controls: *p less than 
0.05, **p less than 0.01, and ***p less 
than 0.005. (C) Bar graph indicating 
differences in PS-STAT3 wild-type and 
KRAS tumor through polymerase chain 
reaction sequencing results. p values 
indicate comparisons versus con-
trols: *p less than 0.05, **p less than 
0.01, and ***p less than 0.005. (D) 
Immunohistochemistry for IL-6 in two 
high expressing cells. Top: stromal cell 
(S) expressing IL-6 (arrow); bottom: 
tumor cells (T) expressing IL-6 (arrow).
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other tumors, we observed (Fig. 1D, bottom panel) tumor cells 
that expressed abundant levels of IL-6. Data on these 10 cases 
are summarized in Table 2. Therefore, IL-6 production in the 
tumors can be produced either in an autocrine fashion by the 
tumor cells or by stromal cells, such as CAFs.
Effects of Combined Siltuximab and 
Erlotinib on NSCLC In Vivo
We next examined how siltuximab affects tumor growth 
in vivo using human lung cancer xenograft models. Using two 
adenocarcinoma cell lines (H1650, H322) and a squamous 
cell carcinoma cell line (H157), we characterized produc-
tion of IL-6 in these cells, their expression of phosphorylated 
STAT3, and the in vitro effects of siltuximab on PY-STAT3. 
Luminex results confirmed basal expression of PY-STAT3 
and PS-STAT3 in all three cell lines (Fig. 2A). As shown in 
Fig. 2B, the H157 and H1650 cells produced high amounts 
of autocrine IL-6, whereas H322 cells produced negligible 
amounts of IL-6. We also examined CAF cells and confirmed 
that CAF produced high levels of IL-6 compared with the 
other cell lines. Regarding the in vitro effects of siltuximab 
on lung cancer cell viability, except for very modest effects on 
H1650 growth, we observed no differences with siltuximab 
treatment versus control treatment (Fig. 2C). Next, we exam-
ined basal PY-STAT3 and responses to IL-6 and siltuximab 
by Western blotting. As shown in the Figure 2D, PY-STAT3 
levels were stimulated by IL-6 in H322 cells and this could be 
repressed by siltuximab. In H1650 and H157 cells, the levels 
of PY-STAT3 were not further increased by exogenous lev-
els of IL-6. Siltuximab repressed PY-STAT3 levels in H1650 
cells, confirming our previous studies.10
Three cell lines were used in xenograft models to study 
the in vivo effects of siltuximab: (1) H322, representing cells 
that produce no autocrine IL-6 but can be stimulated by IL-6 
from the environment; (2) H1650, representing cells that pro-
duce their own autocrine IL-6 that drives STAT3 signaling; 
and (3) H157, representing cells with high autocrine IL-6 yet 
inhibition of IL-6 by siltuximab has no effect on downstream 
signaling. Siltuximab alone and combination treatment with 
siltuximab and erlotinib were examined in these mouse xeno-
graft models. To target both human IL-6 from human cell 
lines and mouse IL-6 produced by murine stromal cells, we 
combined antihuman IL-6 (siltuximab) with antimouse IL-6 
antibody. This is referred to as “siltuximab(+)” in the subse-
quent discussion and figures. We also tested these treatment 
combinations in a coculture model with CAF cells based on 
our results suggesting that stromal cells may be producers of 
IL-6 and this could be important in tumor growth and sensi-
tivity to siltuximab (Fig. 3A-C). Levels of PY-STAT3(Tyr705) 
and IL-6 were examined by immunohistochemistry in a subset 
of these xenograft models and we observed strong evidence 
of both IL-6 and PY-STAT3 (Tyr705) in all tumors examined 
(Fig. 3D). We found that all xenograft models produced simi-
larly abundant IL-6 and we did not observe the intra-tumoral 
heterogeneity seen in patient specimens. We also observe 
IL-6 staining in both tumor and stromal cells. Surprisingly, 
levels of IL-6 were largely independent of cell line histology 
or presence of CAFs. Although a modest reduction of nuclear 
PY-STAT3 (Tyr705) was detected in response to siltuximab(+) 
across all models, these differences were not statistically sig-
nificant (Fig. 3E). Because our previous data showed that 
combined siltuximab plus erlotinib can reduce STAT3 acti-
vation and phosphorylation of serine and tyrosine in H1650 
cell line in vitro, the EGFR inhibitor erlotinib was selected for 
combination strategy in the present study.10
H322 model: Erlotinib alone had a strong inhibitory 
effect on tumor growth, consistent with previously published 
studies.14 Compared with the other models studied below 
(H1650, H157), tumors grew slowly in the H322 model system 
and siltuximab(+) therapy had little effect on the tumors. No 
additional effect of combined erlotinib and siltuximab(+) was 
observed. Addition of CAF cells clearly increased the growth 
of tumors compared with H322 cells alone, and erlotinib 
alone again had a strong effect on tumor growth. However, 
compared with the results with H322 tumors alone, tumors 
with H322 and CAF cells demonstrated strong inhibition of 
growth after single-agent siltuximab(+) therapy. No additional 
effect of combined erlotinib and siltuximab(+) was observed 
in the CAF + H322 model.
H1650 model: Erlotinib, as expected, had a strong inhibi-
tory effect on tumor growth, in this EGFR-mutant lung cancer 
model.12 The tumors grew slowly in the H1650 model system. 
Siltuximab therapy had modest effects on the H1650 tumors 
compared with effects with erlotinib. Combined erlotinib and 
siltuximab(+) had a statistically significant but very modest 
reduction in tumor growth compared with single agents alone. 
Similar to the observations with the H322 tumors, addition 
of CAF cells clearly increased tumor growth compared with 
H1650 tumors alone, and erlotinib again had strong effects on 
growth of these tumors. Compared with the results with H1650 
tumors alone, tumors produced with H1650 and CAF cells dem-
onstrated stronger inhibition of growth after single-agent siltux-
imab(+) therapy. No additional effect of combined erlotinib and 
siltuximab(+) was observed in the CAF + H1650 model.
H157 model: Erlotinib had no effect on tumor growth 
in this squamous cell line with wild-type EGFR, consistent 
TABLE 2.  Interleukin-6 (IL-6) Immunohistochemistry 
Summary
Tumor Histology Tumor IL-6 Stroma IL-6
1 Adeno Negative Negative
2 Adeno Negative Positive
3 Squamous Negative Positive
4 Squamous Negative Positive
5 Adeno Negative Negative
6 Adeno Positive Negative
7 NOS Negative Positive
8 Adeno Negative Negative
9 Adeno Positive Positive
10 Adeno Negative Negative
Ten non–small-cell lung carcinoma tissues were examined for tumor, stromal, or 
both IL-6 presence using IL-6 immunohistochemistry.
Positive, positive for the presence of IL-6 by immunohistochemistry; negative, lack 
of IL-6 signal by immunohistochemistry.
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with previously published results.14 The cells grew briskly and 
aggressively using this model system. Siltuximab(+) therapy 
had little effect on these tumors. This was somewhat expected 
because, although IL-6 levels were observed to be produced 
by the H157 cells, siltuximab had no effect on downstream 
STAT3 signaling in cell culture (Fig. 3C). No additional 
effect of combined erlotinib and siltuximab(+) was observed. 
Results with CAF were identical to those observed with H157 
cells alone, with no increased tumor growth observed with 
coadministration of CAF cells. H157 tumors, with or without 
CAF, did not respond to siltuximab(+), suggesting that H157 
cells are not dependent on the IL-6/STAT3 signaling pathway, 
even with a high expression of IL-6.
Primary explant model: The primary xenograft was 
an adenocarcinoma with wild-type KRAS and EGFR. This 
primary human NSCLC xenograft model closely recapit-
ulates the properties of the parental tumors.15 One of the 
advantages of using direct xenografting of human cancers 
is that there is no clonal selection, and all cellular frac-
tions including stem cell populations existing in a tumor 
are transplanted. We initially attempted to propagate three 
primary xenograft models that had initially grown in immu-
nodeficient mice. However, two of the initial models failed 
to propagate and we abandoned studying these further. The 
third model grew extremely slowly, requiring nearly 50 days 
of growth before robust measurements could be obtained 
and drug treatment experiments (control treatment and sil-
tuximab[+] alone) were started at fifth generation from a 
single primary tumor. We had originally planned to study 
the combination of erlotinib and siltuximab in this model 
but the slow pace resulted in less animals available for 
study. As shown in Figure 4, although both treatment groups 
responded with a slow tumor growth at first, after 36 days 
mice receiving siltuximab(+) had significantly less tumor 
size than control treated mice.
DISCUSSION
The purpose of this study was to examine patterns of 
IL-6 signaling in NSCLC and to determine the effects of neu-
tralizing IL-6 antibodies (siltuximab) on tumor growth. First, 
when we examined patterns of IL-6 expression in NSCLC tis-
sues and correlated these results with tumor histology, EGFR 
FIGURE 2.  Patterns of in vitro interleukin-6 and STAT3 activation in lung cancer cells. H322, H157, and H1650 cells were cul-
tured in 10 ml of RPMI 1640 with 10% fetal bovine serum (FBS), and cancer-associated fibroblasts (CAF) was cultured in 10 ml 
of DMEM with 10% FBS for 48 hours in 10 cm dishes. Protein and culture medium were collected for Luminex or immunoblot 
assay. A, Luminex results show the endogenous levels of PY-STAT3 and PS-STAT3. (B) Luminex results indicate interleukin-6 (IL-6) 
levels from cell culture medium that normalized by cell numbers. (C) CellTiter-GLO assay results performed after 72 hours after 
incubation with siltuximab or phosphate-buffered saline as vehicle control. (D) Immunoblot results indicate PY-STAT3 levels 
change through stimulation with IL-6 or treated with siltuximab. Cells were collected after 10 minutes of IL-6 stimulation or 16 
hours of siltuximab.
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and KRAS mutation status, and downstream activation of 
STAT3 signaling, we found IL-6 to be twice as abundant in 
squamous cell histology versus adenocarcinoma histology. We 
observed no differences in IL-6 production in KRAS-mutant 
adenocarcinoma versus wild-type KRAS adenocarcinoma 
cells. Based on studies that found that KRAS transforma-
tion requires IL-6, we had hypothesized that KRAS-mutant 
cancers would have more IL-6, but this was not the case.16,17 
However, given the small sample size, we were unable to 
determine whether IL-6 is higher in tumors with activating 
EGFR mutations, as has been observed in lung cancer cell 
lines.13 We had hypothesized that high levels of IL-6 in the 
tumor would translate to high levels of activated PY-STAT3 in 
the tumor, but this result was not observed. This finding may 
FIGURE 3.  Effects of siltuximab(+) in mouse xenograft models of lung cancer. CD-1 nu/nu mice were divided into four treat-
ment groups of 15 mice of each for H322, H1650, and H157 xenograft models The single-agent treated group was exposed to 
10 mg/kg of each antihuman interleukin-6 (IL-6) and antimouse IL-6 antibodies (siltuximab +) three times per week or 50 mg/kg  
of erlotinib daily; the combination group was exposed to both siltuximab(+) and erlotinib. The control group was treated 
identically as the single-agent and combined groups, but with control vehicle (phosphate-buffered saline) intraperitoneally and 
0.5% of hydroxypropyl methylcellulose orally. Tumor growth (in mm3) was assessed every 2–3 days. Error bars indicate varia-
tion of tumor volume, and p values indicate the significant comparison in two groups: *p less than 0.05, **p less than 0.01, and 
***p less than 0.005. A, Tumor growth in H322 and H322 + CAF xenografts, with significant differences shown in control and 
siltuximab(+) groups. (B) Tumor growth in H1650 and H1650 + cancer-associated fibroblast (CAF) xenografts, with significant 
differences observed in control versus siltuximab(+) and in erlotinib versus combination group. (C) Tumor growth in H157 and 
H157 + CAF xenograft. No significant differences were found. (D) Representative images of tumor cells in cell line xenograft 
models, demonstrating IL-6 and PY-STAT3 (Tyr705) staining. Black scale bars represent 40 μM. (E) Quantification of nuclear 
PY-STAT3(Tyr705) using Spectrum nuclear algorithm (Aperio). Graphs show mean percentage of nuclei staining positive per 
treatment (N = 3), with error bars representing SD. All p values greater than 0.05 for control versus siltuximab(+).
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suggest additional complexities in regulation of STAT3 phos-
phorylation beyond simply reflecting intra-tumor IL-6 levels. 
In addition, this result suggests that PY-STAT3 in tumor cells, 
which can be assayed by immunohistochemistry, may not be 
accurate enough to be used as a predictive marker to identify 
tumors driven by high IL-6 levels and therefore most appro-
priate for siltuximab therapy. Interestingly, KRAS mutation 
was related to serine phosphorylation of STAT3, suggesting 
that downstream MAP kinase activation by KRAS mutations 
may signal to STAT3, as has been suggested in cell culture 
experiments.18,19
Our second aim was to determine the effects of IL-6 neu-
tralizing antibodies on xenograft lung cancer model systems 
and the combination effects with EGFR inhibition by erlotinib 
and effects of stromal production of IL-6 by CAF cells. We used 
CAF cells along with tumor cells (H1650, H322, and H157) 
in our in vivo models, because we observed some tumors with 
abundant production of IL-6 by stromal cells (Fig. 1D). IL6 
can be produced by both tumor cells and stromal cells in the 
tumor microenvironment. We and others previously demon-
strated that lung cancer cells can express IL-6 and IL-6 recep-
tor subunits.11,20 Conversely, hepatic cells, mesenchymal stem 
cells, cancer-associated fibroblasts, and osteoclasts have been 
reported in various contexts to produce IL-6.21–25 In the H322 
model, we observed increased tumor growth by coadministra-
tion of CAF cells that could be inhibited by IL-6 blockade 
(siltuximab[+]). We interpret these results to mean that some 
subsets of lung cancer tumors may be driven by stromal IL-6 
that can be neutralized by siltuximab(+), resulting in inhibition 
of tumor growth. In this model, and in the H1650 and H157, 
we observed no additional benefit of co-targeting EGFR and 
IL-6. Similar findings were observed in the H1650 cell, where 
CAF cells increased tumor volume that could be blocked with 
siltuximab. We also observed some modest reduction in tumor 
growth in H1650 tumors alone, consistent with the autocrine 
signaling of IL-6 to downstream STAT3, although the effect 
was less pronounced compared with erlotinib monotherapy. 
Finally, the H157 squamous cell line was completely resistant 
to IL-6 neutralizing antibody therapy either with or without 
CAF cells. This cell line appears to have IL-6-independent 
growth. Lastly, we examined one primary explant model 
with wild-type EGFR and KRAS status and found modest 
effects of tumor growth later in the experimental timeline. 
This experiment was somewhat provocative as some tumors 
stopped growing and regressed toward later days of treat-
ment. More experiments will be necessary to fully determine 
whether similar results would be observed in a larger number 
of animal tumor models.
This study has implications for potential use of IL-6 
neutralizing antibodies for lung cancer. First, we observed 
more IL-6 production in squamous cell tumors; thus, further 
experiments in additional squamous cell models, both cell line 
xenograft and primary explant, should be considered. Whereas 
some targetable lesions have been observed in squamous cell 
lung cancer (DDR2 mutations, FGFR1 gene amplification, 
mutations), the tumor type has lacked success in targeted 
agent efficacy in clinic compared with adenocarcinoma.26–30 
Our single H157 model should not dissuade further experi-
ments in squamous cell models. Second, our animal xenograft 
experiments suggest that IL-6 neutralizing antibodies may 
work best in tumors that have stromal production of IL-6 that 
is driving tumor cell growth in a paracrine manner. Further 
studies examining CAF cells in human tumor samples, their 
production of IL-6, and measurements of IL-6-driven sig-
naling in the corresponding tumor cells (perhaps with IL-6 
immunohistochemistry to look for stromal cells expressing 
IL-6) may identify subsets of tumors that benefit from IL-6-
neutralizing antibodies such as siltuximab. Third, we observed 
no clinically relevant improvement in tumor growth with com-
bined erlotinib and siltuximab compared with erlotinib alone, 
at least in the models studied. Nonetheless, in both the H1650 
and H322 cell xenograft models, siltuximab did have some 
degree of single-agent activity, especially in coculture models 
with CAF cells.
We acknowledge that our study may have some limita-
tions. Tumors with EGFR mutations should be further studied 
for IL-6 levels and STAT3 activation. Previous studies have 
suggested that tumor cells with activating EGFR mutations 
drive STAT3 signaling through IL-6 production and targeting 
IL-6 impaired tumorigenesis.13 We had inadequate numbers 
of EGFR-mutant tumors to make any conclusions about IL-6 
production in these tumors. This is also important for further 
study given a potential role of IL-6 in driving resistance to 
EGFR-TKIs.12 However, both of these studies, along with 
our own results, suggest that IL-6 targeting using siltuximab 
may have benefit in NSCLC subtypes. Our results are lim-
ited in squamous cell models because we only tested the H157 
model that grows well in xenografts. Further studies should 
be considered in squamous cell models, as our tumor stud-
ies suggested more IL-6 production in these tumor types. Use 
of squamous cell lines from conditionally reprogrammed cell 
models may expand the ability to study more squamous cell 
models. Likewise, our use of primary xenograft models was 
FIGURE 4.  Effects of siltuximab(+) on non–small-cell lung 
cancer primary explant model. NOD/SCID mice were divided 
into two groups with six pairs of mice for each primary 
xenograft, as described in Materials and Methods. The single-
agent treatment group was given 10 mg/kg of siltuximab(+) 
(injected intraperitoneally) three times per week; controls 
were given the same volume of phosphate-buffered saline. 
Tumor growth (in mm3) was assessed every 2–3 days. Error 
bars indicate variation of tumor volume, and p values indicate 
the significant comparison in two groups: *p less than 0.05, 
**p less than 0.01, ***p less than 0.005.
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limited and further studies in these systems could be more 
informative. We used simple subcutaneous xenograft models, 
and more striking results may be obtained in orthotopic mod-
els, especially in organs that produce higher levels of IL-6, 
such as bone.31 It would be interesting and important to con-
sider these additional types of models, as bone metastasis is 
relatively common in lung cancer and other solid tumors. We 
limited our studies to tumor growth and therefore may have 
missed some important effects on tumor invasion and metas-
tasis. Some studies have suggested that IL-6 may be important 
in lung cancer stem cells, as opposed to the bulk tumor cells.32 
Beyond direct targeting of tumor cells, targeting IL-6-related 
inflammation may have beneficial effects on patient quality of 
life through improvement in cachexia and lung cancer-related 
anemia.33 In conclusion, our results and those of others sug-
gest that further study of IL-6 targeting with siltuximab should 
be considered in human clinical trials. Our studies would sug-
gest that IL-6 production in the tumor stroma may be a sur-
rogate marker for siltuximab activity and should be examined 
in patient samples along with EGFR mutation status and prior 
response to EGFR-TKI therapy.
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